These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
743 related articles for article (PubMed ID: 29781586)
21. Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis. Zheng JN; Yang QR; Zhu GQ; Pan L; Xia JX; Wang Q Mod Rheumatol; 2020 Jul; 30(4):687-695. PubMed ID: 31269839 [No Abstract] [Full Text] [Related]
22. Treatment of systemic sclerosis. Pope JE Rheum Dis Clin North Am; 1996 Nov; 22(4):893-907. PubMed ID: 8923602 [TBL] [Abstract][Full Text] [Related]
23. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis. Ueda T; Sakagami T; Kikuchi T; Takada T Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675 [TBL] [Abstract][Full Text] [Related]
25. Worldwide Expert Agreement on Updated Recommendations for the Treatment of Systemic Sclerosis. de Vries-Bouwstra JK; Allanore Y; Matucci-Cerinic M; Balbir-Gurman A J Rheumatol; 2020 Feb; 47(2):249-254. PubMed ID: 31043545 [TBL] [Abstract][Full Text] [Related]
26. Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial. Naidu GSRSNK; Sharma SK; Adarsh MB; Dhir V; Sinha A; Dhooria S; Jain S Rheumatol Int; 2020 Feb; 40(2):207-216. PubMed ID: 31813058 [TBL] [Abstract][Full Text] [Related]
27. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326 [TBL] [Abstract][Full Text] [Related]
28. Current treatment options in systemic Sclerosis (Scleroderma). Stummvoll GH Acta Med Austriaca; 2002; 29(1):14-9. PubMed ID: 11899748 [TBL] [Abstract][Full Text] [Related]
29. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II. Tashkin DP; Volkmann ER; Tseng CH; Roth MD; Khanna D; Furst DE; Clements PJ; Theodore A; Kafaja S; Kim GH; Goldin J; Ariolla E; Elashoff RM Chest; 2017 Apr; 151(4):813-820. PubMed ID: 28012804 [TBL] [Abstract][Full Text] [Related]
30. Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. Assassi S; Li N; Volkmann ER; Mayes MD; Rünger D; Ying J; Roth MD; Hinchcliff M; Khanna D; Frech T; Clements PJ; Furst DE; Goldin J; Bernstein EJ; Castelino FV; Domsic RT; Gordon JK; Hant FN; Shah AA; Shanmugam VK; Steen VD; Elashoff RM; Tashkin DP Arthritis Rheumatol; 2021 Jun; 73(6):1005-1013. PubMed ID: 33350170 [TBL] [Abstract][Full Text] [Related]
32. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series. Yilmaz N; Can M; Kocakaya D; Karakurt S; Yavuz S Int J Rheum Dis; 2014 Nov; 17(8):923-8. PubMed ID: 24864029 [TBL] [Abstract][Full Text] [Related]
33. Management of Raynaud's phenomenon and digital ulcers in systemic sclerosis. Botzoris V; Drosos AA Joint Bone Spine; 2011 Jul; 78(4):341-6. PubMed ID: 21183379 [TBL] [Abstract][Full Text] [Related]
34. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease. Higuero Sevilla JP; Memon A; Hinchcliff M Arthritis Res Ther; 2023 Jul; 25(1):118. PubMed ID: 37422652 [TBL] [Abstract][Full Text] [Related]
35. [Systemic sclerosis]. Tamborrini G; Distler M; Distler O Med Monatsschr Pharm; 2008 May; 31(5):162-70; quiz 171-2. PubMed ID: 18552072 [TBL] [Abstract][Full Text] [Related]
36. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials. Au K; Khanna D; Clements PJ; Furst DE; Tashkin DP Curr Rheumatol Rep; 2009 Apr; 11(2):111-9. PubMed ID: 19296883 [TBL] [Abstract][Full Text] [Related]
37. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O; Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of Mycophenolate Mofetil and Oral Cyclophosphamide on Skin Thickness: Post Hoc Analyses From Two Randomized Placebo-Controlled Trials. Namas R; Tashkin DP; Furst DE; Wilhalme H; Tseng CH; Roth MD; Kafaja S; Volkmann E; Clements PJ; Khanna D; Arthritis Care Res (Hoboken); 2018 Mar; 70(3):439-444. PubMed ID: 28544580 [TBL] [Abstract][Full Text] [Related]
40. Agreement with guidelines from a large database for management of systemic sclerosis: results from the Canadian Scleroderma Research Group. Pope J; Harding S; Khimdas S; Bonner A; ; Baron M J Rheumatol; 2012 Mar; 39(3):524-31. PubMed ID: 22247347 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]